Genotyping Too Slow to Matter? Think Again

Myth: Genotyping takes too long to impact clinical decision-making.

Turnaround Time

Turnaround time is everything in the modern clinical lab. Historically, genotyping was seen as too slow – often a send-out test that couldn’t meet urgent needs. Today, that view is outdated.

Molecular Platforms have Improved Dramatically.

Molecular platforms have improved dramatically. Microarray-based assays with automated DNA extraction can be resulted quickly.

Even next-generation sequencing now allows a 24–72-hour turnaround time for many blood group genotyping tests. In urgent situations, some centers can deliver same-day genotyping results – particularly for critical scenarios like prenatal fetal RhD typing or high-risk oncology patients needing matched blood.

Genotyping Can Help Make the Next Transfusion Safer, Faster, and Better Matched.

Even when genotyping results aren’t needed in “real time,” they still shape future care. A genotyping result is often done once but then stored in the laboratory information system and reused repeatedly – avoiding future uncertainty and speeding up antibody identification workups for that patient. In this way, genotyping is like preventive medicine in transfusion: not every test has to be STAT, but every result can help make the next transfusion safer, faster, and better matched.

Streamlining Long-Term Care

In summary, while we strive for quick turnaround times, genotyping no longer means waiting weeks. With current technology, it can be both timely and impactful, guiding acute transfusion management when necessary and streamlining long-term care for transfusion-dependent patients. Far from being “too slow to matter,” genotyping increasingly fits within clinical timelines – and its benefits to patient safety and inventory management are well worth it.